# A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients

> **NCT02096601** · PHASE1 · COMPLETED · sponsor: **NeuroDerm Ltd.** · enrollment: 16 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** LD/CD SC solution
- **DRUG:** Entacapone

## Key facts

- **NCT ID:** NCT02096601
- **Lead sponsor:** NeuroDerm Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-11
- **Primary completion:** 2015-03-15
- **Final completion:** 2015-03-15
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2024-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02096601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02096601, "A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02096601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*